# **Special Issue**

# Frontiers in Pathogenesis and Therapeutics of Cancer

# Message from the Guest Editors

In cancer treatment, the ultimate goal is to offer accurate and personalized treatment according to the specific situation of patients. This Special Issue of the Journal of Personalized Medicine aims to explore the latest innovative treatments for all kinds of cancers. such as breast cancer, leukemia, endometrial carcinoma, and so on. Our goal is to demonstrate the scientific advances in this field and pave the way toward personalized medicine for treating cancers. In this Special Issue, original research articles and reviews are welcome. We are pleased to invite you to contribute studies using basic science, clinical, and populationbased approaches, including, but not limited to: radiotherapy chemotherapy immunotherapy CART immunotherapy targeted therapy

# **Guest Editors**

Dr. Yong Wu

cell therapy

- 1. Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA
- 2. David Geffen UCLA School of Medicine, Los Angeles, CA, USA
- 3. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

# Dr. Jin Zhang

Department of Surgery, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

## Deadline for manuscript submissions

closed (10 January 2023)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/108843

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

### **Author Benefits**

# **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

